AIM ImmunoTech Inc. (AIM)
$0.16-5.88%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $544,566
- Beta
- 1.27
- P/E (TTM)
- -0.04
- Short % float
- 50.66%
- Days to cover
- 1.0
- SI change
- -49.1%
- 1W
- -11.11%
- 1M
- -23.81%
- vs SPY 1W
- -10.97%
- vs SPY 1M
- -26.32%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 0
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-112.1%
GROSS-125
OP-11638
NET-15021
[VALUATION]
P/E TTM-0.04
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.36
P/FCF-
EV/EBITDA-0.03
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E50.63
ALTMAN Z-
CURR RATIO2.11
ND/EBITDA-
BETA1.27
Company news
FAQ
- What is LOPJLB’s current signal on AIM?
- LOPJLB’s latest quantitative signal on AIM ImmunoTech Inc. (AIM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AIM in?
- AIM ImmunoTech Inc. (AIM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does AIM ImmunoTech Inc. (AIM) do?
- AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, a…